Breakthroughs Blog

Breakthroughs brings you stories of bright ideas and bold innovations in global health.

The Latest
Emily Conron
Research in action in Uganda

Last week GHTC led a learning trip with US Congressional staff to Uganda to see first hand the impact of US government funding for global health R&D. Check out our favorite moments from the week.

Recent

Research Roundup: an aerosol vaccine for Ebola, software to enable clinical trials, an antibody against dengue fever, and more

An experimental, aerosol vaccine completely prevented infection from Ebola in monkeys, and will be tested in human clinical trials shortly.

GHTC
Read More
PATH/Gabe Bienczycki
How to accelerate innovation to solve the world's most urgent health issues

In this post, Amie Batson, MBA—chief strategy officer at GHTC member PATH—discusses a new PATH-led initiative to identify and showcase lifesaving innovations with the promise to transform global health by 2030 and offers insights into what it will take to accelerate the impact of innovation. This post originally appeared in the Innovation Countdown 2030 Report: Reimagining Global Health.

PATH
Read More
Research Roundup: bacteria-eating viruses, experimental HIV and flu vaccines, and pharmaceutical law

With the looming threat of a post-antibiotic era—in which minor infections are fatal due to growing drug resistance—world leaders are examining remedies for treating bacterial infections from the pre-antibiotic era.

GHTC
Read More
Passing the ball: DNDi transfers malaria therapies to MMV

The Drugs for Neglected Disease initiative (DNDi) and the Medicines for Malaria Venture (MMV)—nonprofit product development partnerships (PDPs) and members of the Global Health Technologies Coalition—have teamed up to ensure two treatments for malaria continue to reach the patients who need them most.

GHTC
Read More
Research Roundup: Drug-resistant TB, regulatory reform in India, a malaria vaccine, and more

A new study published in PLOS Medicine indicates that multi-drug resistant tuberculosis (TB) is less contagious than drug-susceptible TB.

GHTC
Read More
Architect of the Capitol
Celebrating America’s contributions to global health innovation

This Independence Day, GHTC is taking a break from our cookouts and parades to celebrate America’s extraordinary contributions to advancing innovation to save lives around the world.

Read More
PATH/Doune Porter
Four reasons to visit the Contraceptive Technology Innovation Exchange today

Over the past several decades, overall investment in contraceptive R&D has declined dramatically. The result? Renewed commitment and partnerships will be required to ensure that new contraceptive methods advance through the development pipeline and that access to the final products is affordable and equitable.

FHI360
Read More
Research Roundup: a new contraceptive option, China’s role in global health R&D, and vaccines for MERS and pneumonia

Last week, GHTC member PATH launched the Caya® contoured diaphragm in the United States, after developing and testing nearly 200 prototypes to ensure the product was safe, effective, and user friendly.

GHTC
Read More
PATH/Christopher Nelson
Research Roundup: a promising antimalarial and leishmaniasis vaccine, diagnostics for tuberculosis, and more

The Medicines for Malaria Venture (MMV)—a member of the GHTC—and the University of Dundee’s Drug Discovery Unit have developed an antimalarial compound that could treat drug-resistant cases of malaria with a single dose.

GHTC
Read More
PATH/Nguyen Ba Quang
Research Roundup: Middle East Respiratory Syndrome R&D, G7 support for antimicrobial and neglected tropical disease R&D, patient safety and the 21st Century Cures Act, and the contraceptive pipeline

The zoonotic Middle East Respiratory Syndrome (MERS), which World Health Organization (WHO) Director-General Dr. Margaret Chan called “a threat to the entire world” has spread to South Korea. More than 100 cases and 10 deaths have been reported, making it the largest outbreak outside of the Arabian Peninsula.

GHTC
Read More
Research Roundup: cross-sector partnerships to advance drug discovery, global recommendations for contraceptive use, and a diagnostic that detects lifetime viral exposure

The Drugs for Neglected Diseases initiative (DNDi)—a member of the GHTC—is partnering with pharmaceutical companies Eisai Co., Shionogi & Co., Takeda Pharmaceutical, and AstraZeneca to accelerate early-stage research for drugs against Chagas and leishmaniasis.

GHTC
Read More
World Health Assembly roundup: News on global health research and innovation

The 68th World Health Assembly (WHA) in Geneva wrapped up last week after addressing several items that will shape the next few years of global health innovation.

GHTC
Read More
New legislation would strengthen USAID’s role in global health R&D

Update: The Global Health Technologies Coalition is excited to announce that the Global Health Innovation Act (H.R. 2241) passed the House of Representatives on December 18.

GHTC
Read More
Research Roundup: priority review voucher sells for record price, WHO action to address antimicrobial resistance, and more

The French pharmaceutical company Sanofi purchased a priority review voucher (PRV)—which entitles the owner to an expedited review of a future product by the US Food and Drug Administration (FDA)—for US$245 million last week.

GHTC
Read More
21st Century Cures Act: What the global health community needs to know

Last week, the House Energy and Commerce Committee unanimously voted to approve the 21st Century Cures Act—a bill that aims to speed the development, approval, and introduction of new health technologies.

Read More
CDC/Melissa Dankel
Research Roundup: US and European efforts to address growing antimicrobial resistance and legislation to advance medical breakthroughs

Members of the European Parliament are calling on the European Commission to adopt a resolution to combat the growing threat of antimicrobial resistance—which kills 25,000 Europeans annually.

GHTC
Read More
PATH/Evelyn Hockstein
Four reasons now is the time to ramp up investment in HIV/AIDS vaccine R&D

This Monday, May 18 was HIV Vaccine Awareness Day (HVAD), and GHTC members AVAC, the International AIDS Vaccine Initiative (IAVI), and the Bill & Melinda Gates Foundation convened leaders in the field to discuss the state of HIV/AIDS vaccine research and development (R&D).

GHTC
Read More
PATH/Christopher Nelson
Research Roundup: Big Pharma’s role in antibiotic R&D, clinical trials for Ebola vaccines and drug-resistant tuberculosis treatments, and more

How can we get Big Pharma to invest in low-cost antibiotic research and development (R&D)?

GHTC
Read More
Will Boase
Research Roundup: inclusion of women in clinical trials, the future of vaccines, and diagnostics for counterfeit medicines and parasitic worms

United States Representatives Jim Cooper (D-TN) and Cynthia Loomis (R-WO) introduced the Research for All Act last week which calls for the inclusion of more women in clinical trials for products submitted for US Food and Drug Administration (FDA) approval.

GHTC
Read More
Mothers of innovation: Five mothers who have transformed global health

Breakthrough ideas are like children—they start small, they need constant nurturing, they don’t always develop according to schedule, but they change lives forever.

Read More